Market Overview
The Artificial Pancreas Device System
market is predicted to develop at a compound annual growth rate (CAGR) of 8.22%
from 2024 to 2033, when it is projected to reach USD 1,512 Million, based on an
average growth pattern. The market is estimated to reach a value of USD 360 Million
in 2024.
SOURCE: We Market Research
The Artificial
Pancreas Device System is a cutting-edge medical device used to control blood
sugar levels in diabetics. It replicates the actions of a functional pancreas
by combining automated insulin delivery with continuous glucose monitoring. In
order to provide accurate management and lower the risk of hypo- and
hyperglycemia, APDS+ measures blood glucose levels in real-time and modifies
insulin delivery accordingly. By reducing the strain of continuous observation
and manual insulin injection, this ground-breaking device improves the quality
of life for patients and presents a viable way to better manage diabetes and
achieve improved health outcomes.
Multiple factors
are driving the market for Artificial Pancreas Device System (APDS). The need
for sophisticated diabetes management solutions is fueled, first and foremost,
by the growing incidence of diabetes worldwide. Adoption is also influenced by
growing knowledge of the advantages of APDS, such as better glycemic control
and a lower risk of problems. The accessibility and use of APDS are improved by
technological developments such as downsizing and improved connectivity.
Policies that facilitate reimbursement and favorable regulatory frameworks also
promote market expansion. The requirement for ongoing glucose monitoring and
the increasing emphasis on individualized healthcare are further factors
driving market growth. Together, these factors are fueling the APDS market's
expansion.
Market Scope
Report Attributes |
Description |
Market Size in 2024 |
USD 360 Million |
Market Forecast in 2033 |
USD 1,512 Million |
CAGR % 2024-2033 |
8.22% |
Base Year |
2023 |
Historic Data |
2016-2022 |
Forecast Period |
2024-2033 |
Report USP
|
Production, Consumption, company share, company
heatmap, company production capacity, growth factors and more |
Segments Covered |
By Device Type, by
Treatment Type, by End User and By Region |
Regional Scope |
North America, Europe, APAC, South America and Middle
East and Africa |
Country Scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic
Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia;
Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa;
Nigeria |
Artificial Pancreas Device System Industry: Dynamics
& Restrains
Market Drivers
The increasing
incidence of diabetes worldwide - The
increasing global prevalence of diabetes is largely responsible for the growth
of the artificial pancreas device market. Modern methods are increasingly
needed to effectively manage diabetes since the condition is spreading more and
more. Artificial pancreas systems offer a novel approach by automating insulin
delivery through continuous glucose monitoring, hence enhancing glycemic
control and reducing the likelihood of problems. The increased prevalence of
diabetes is driving a need for innovative technologies, such artificial
pancreas devices. Patients and healthcare professionals are searching for more
effective diabetes management alternatives, which is driving market expansion.
Patient
Preference for Convenience and Lifestyle Integration - The market for artificial pancreas devices systems is mostly driven
by patient preferences for ease and lifestyle integration. Patients can lead
more flexible lifestyles while still maintaining good glucose control thanks to
these devices, which provide a more efficient and minimally intrusive approach
to diabetes care. Artificial pancreas systems, with features like automatic insulin
delivery and continuous glucose monitoring, ease the strain of constant
monitoring and manual insulin administration, improving convenience and quality
of life for diabetics. The market for artificial pancreas systems is expanding
and progress in diabetes management technology is being driven by patients'
increasing preference for comfort and seamless integration into their everyday
routines.
Market restrains
The high cost of
devices - The Artificial Pancreas Device System
Market is significantly constrained by the high cost of the devices. These
cutting-edge devices frequently have high upfront costs associated with
purchase, installation, and upkeep. For many patients, especially those with
little financial resources or inadequate insurance coverage, such fees may be
prohibitive. Budgetary restrictions may also deter healthcare organizations and
providers from investing in artificial pancreas technology. Therefore, the cost
barrier prevents a larger patient population from benefiting from sophisticated
diabetes care options, thereby impeding market growth and limiting the adoption
and accessibility of these game-changing technologies.
We Market
Research: Artificial Pancreas Device
System Dashboard
Our marketing platform offers a comprehensive dashboard that provides clients with valuable insights into market trends over the years. Included below is a sample image of our dashboard, and specific PDF logins will be furnished to grant access to this insightful tool.
Artificial Pancreas Device System Segmentation
Market- By Device Type Analysis
By Device Type, the Artificial Pancreas Device System Market is Categories into Threshold Suspended Device System, Control to Range (CTR) System, Control to Target(CTT) System. The Control to Range (CTR) System segment accounts for the largest share of around 40% in 2024.
The market segment of the Artificial
Pancreas Device System Market is driven by the Control to Range (CTR) System's
ability to provide customized glucose control within a predetermined range,
providing patients with greater stability and flexibility in managing their
diabetes. Patient satisfaction is increased and the risk of hypo- or
hyperglycemia episodes is reduced with this adaptable approach.
The
following segments are part of an in-depth analysis of the global Artificial
Pancreas Device System market:
Market Segments |
|
By Treatment Type |
·
Bi-hormonal ·
Insulin Only ·
Hybrid |
By End-Users |
·
Hospitals ·
Medical ·
Centers |
Artificial Pancreas Device System Industry: Regional Analysis
North America Market Forecast
North America dominate the Artificial Pancreas Device System Market with the highest revenue generating market with share of more than 49%. The market for artificial pancreas devices (APDS) in North America is driven by the region's high diabetes prevalence, advanced healthcare system, and advantageous reimbursement guidelines. The adoption of APDS is accelerated by the presence of significant market players and research institutions, which is fueled by growing awareness and technological improvements.
Europe Market Statistics
Europe is the
second-largest market for Artificial Pancreas Device System. The number of
people with diabetes is rising across Europe, and the benefits of APDS are
becoming more widely known, accompanied by encouraging government initiatives.
Research and development expenditures as well as advantageous regulatory
frameworks encourage the region's adoption of cutting-edge diabetes treatment
technologies, which in turn propels the expansion of the APDS market.
Asia Pacific Market Forecasts
Asia Pacific is expected
to be the fastest-growing market for Artificial Pancreas Device System during
the forecast period. The Asia Pacific region's rising diabetes prevalence has
been attributed to both rapid increases in healthcare spending and
technological advancements. As a result of government initiatives and raised
awareness, APDS is being adopted in China, India, and Japan, demonstrating the
region's growing significance in the global APDS market.
Key Market Players
The Artificial
Pancreas Device System Market is dominated by a few large companies, such as
·
Cellnovo Group SA
·
DreaMed Diabetes Ltd.
·
Beta Bionics, Inc.
·
Bigfoot Biomedical, Inc.
·
Insulet Corporation
·
Medtronic plc
·
Admetsys Corporation
·
Diabeloop SA
·
TypeZero Technologies LLC
·
Tandem Diabetes Care, Inc.
·
Others
Recent Developments:
·
June 2020, Tandem Diabetes
Care, Inc. and Abbott Laboratories have a distribution arrangement that allows
Tandem to sell its products in a number of foreign regions. Tandem was able to
reach a wider consumer base and increase its market presence thanks to the
deal.
1.
Global
Artificial Pancreas Device System Market Introduction and Market Overview
1.1. Objectives of the Study
1.2. Global Artificial Pancreas
Device System Market Scope and Market Estimation
1.2.1. Global Artificial Pancreas
Device System Overall Market Size, Revenue (US$ Mn), Market CAGR (%), Market
forecast (2023 - 2033)
1.2.2. Global Artificial Pancreas
Device System Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2033
1.3. Market Segmentation
1.3.1. Component of Global Artificial
Pancreas Device System Market
1.3.2. Technology of Global Artificial
Pancreas Device System Market
1.3.3. End-user of Global Artificial
Pancreas Device System Market
1.3.4. Region of Global Artificial
Pancreas Device System Market
2.
Executive Summary
2.1. Global Artificial Pancreas Device System Market Industry Trends under
COVID-19 Outbreak
2.1.1. Global COVID-19 Status Overview
2.1.2. Influence of COVID-19 Outbreak
on Global Artificial Pancreas Device
System Market Industry Development
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Limitations
2.2.3. Opportunities
2.2.4. Impact Analysis of Drivers and
Restraints
2.3. Pricing Trends Analysis &
Average Selling Prices (ASPs)
2.4. Key Mergers & Acquisitions,
Expansions, JVs, Funding / VCs, etc.
2.5. Porter’s Five Forces Analysis
2.5.1. Bargaining Power of Suppliers
2.5.2. Bargaining Power of Buyers
2.5.3. Threat of Substitutes
2.5.4. Threat of New Entrants
2.5.5. Competitive Rivalry
2.6. Value Chain / Ecosystem Analysis
2.7. Russia-Ukraine War Impacts
Analysis
2.8. Economic Downturn Analysis
2.9. Market Investment Opportunity
Analysis (Top Investment Pockets), By Segments & By Region
3.
Global Artificial Pancreas
Device System Market Estimates &
Historical Trend Analysis (2019 - 2022)
4.
Global Artificial Pancreas
Device System Market Estimates &
Forecast Trend Analysis, by DEVICE TYPE
4.1. Global Artificial Pancreas
Device System Market Revenue (US$ Mn) Estimates and Forecasts, by DEVICE TYPE,
2019 to 2033
4.1.1. Threshold Suspended Device
System
4.1.2. Control to Range (CTR) System
4.1.3. Control to Target(CTT) System
5.
Global Artificial Pancreas
Device System Market Estimates &
Forecast Trend Analysis, by Treatment Type
5.1. Global Artificial Pancreas Device
System Market Revenue (US$ Mn) Estimates and Forecasts, by Treatment Type, 2019
to 2033
5.1.1. Bi-hormonal
5.1.2. Insulin Only
5.1.3. Hybrid
6.
Global Artificial Pancreas
Device System Market Estimates &
Forecast Trend Analysis, by End-user
6.1. Global Artificial Pancreas Device
System Market Revenue (US$ Mn) Estimates and Forecasts, by End-user, 2019 to 2033
6.1.1. Hospitals
6.1.2. Medical
6.1.3. Centers
7.
Global Artificial Pancreas
Device System Market Estimates &
Forecast Trend Analysis, by Region
7.1. Global Artificial Pancreas
Device System Market Revenue (US$ Mn) Estimates and Forecasts, by Region, 2019
to 2033
7.1.1. North America
7.1.2. Europe
7.1.3. Asia Pacific
7.1.4. Middle East & Africa
7.1.5. South America
8.
North
America Artificial Pancreas Device System Market: Estimates & Forecast Trend Analysis
8.1.
North
America Artificial Pancreas Device System Market Assessments & Key Findings
8.1.1. North America Artificial
Pancreas Device System Market Introduction
8.1.2. North America Artificial
Pancreas Device System Market Size Estimates and Forecast (US$ Million) (2019 –
2033)
8.1.2.1. By DEVICE TYPE
8.1.2.2. By Treatment Type
8.1.2.3. By End-user
8.1.2.4. By Country
8.1.2.4.1. The U.S.
8.1.2.4.2. Canada
8.1.2.4.3. Mexico
9.
Europe
Artificial Pancreas Device System Market: Estimates & Forecast Trend Analysis
9.1. Europe Artificial Pancreas
Device System Market Assessments & Key Findings
9.1.1. Europe Artificial Pancreas
Device System Market Introduction
9.1.2. Europe Artificial Pancreas
Device System Market Size Estimates and Forecast (US$ Million) (2019 – 2033)
9.1.2.1. By DEVICE TYPE
9.1.2.2. By Treatment Type
9.1.2.3. By End-user
9.1.2.4.
By
Country
9.1.2.4.1. Germany
9.1.2.4.2. U.K.
9.1.2.4.3. France
9.1.2.4.4. Italy
9.1.2.4.5. Spain
9.1.2.4.6. Russia
9.1.2.4.7. Rest of Europe
10. Asia Pacific Artificial
Pancreas Device System Market:
Estimates & Forecast Trend Analysis
10.1. Asia Pacific Market Assessments
& Key Findings
10.1.1. Asia Pacific Artificial Pancreas
Device System Market Introduction
10.1.2. Asia Pacific Artificial Pancreas
Device System Market Size Estimates and Forecast (US$ Million) (2019 – 2033)
10.1.2.1. By DEVICE TYPE
10.1.2.2. By Treatment Type
10.1.2.3. By End-user
10.1.2.4. By Country
10.1.2.4.1. China
10.1.2.4.2. Japan
10.1.2.4.3. India
10.1.2.4.4. Australia
10.1.2.4.5. South Korea
10.1.2.4.6. ASEAN
10.1.2.4.7. Rest of Asia Pacific
11. Middle East & Africa Artificial
Pancreas Device System Market: Estimates
& Forecast Trend Analysis
11.1. Middle East & Africa Market
Assessments & Key Findings
11.1.1. Middle
East & Africa Artificial
Pancreas Device System Market Introduction
11.1.2. Middle
East & Africa Artificial
Pancreas Device System Market Size Estimates and Forecast (US$ Million) (2019 –
2033)
11.1.2.1. By DEVICE TYPE
11.1.2.2. By Treatment Type
11.1.2.3. By End-user
11.1.2.4. By Country
11.1.2.4.1. U.A.E.
11.1.2.4.2. Saudi Arabia
11.1.2.4.3. Egypt
11.1.2.4.4. South Africa
11.1.2.4.5. Rest of Middle East & Africa
12. South America
Artificial Pancreas Device System Market:
Estimates & Forecast Trend Analysis
12.1. South America Market Assessments
& Key Findings
12.1.1. South America Artificial
Pancreas Device System Market Introduction
12.1.2. South America Artificial
Pancreas Device System Market Size Estimates and Forecast (US$ Million) (2019 –
2033)
12.1.2.1. By DEVICE TYPE
12.1.2.2. By Treatment Type
12.1.2.3. By End-user
12.1.2.4. By Country
12.1.2.4.1. Brazil
12.1.2.4.2. Argentina
12.1.2.4.3. Colombia
12.1.2.4.4. Rest of South America
13. Competition Landscape
13.1. Global Artificial Pancreas
Device System Market Competition Matrix & Benchmarking, by Leading Players
/ Innovators / Emerging Players / New Entrants
13.2. Global Artificial Pancreas
Device System Market Competition White Space Analysis, By End-user
13.3. Global Artificial Pancreas
Device System Market Competition Heat Map Analysis, By End-user
13.4. Global Artificial Pancreas
Device System Market Concentration & Company Market Shares (%) Analysis,
2022
14. Company Profiles
14.1.
Cellnovo Group SA
14.1.1. Company Overview & Key Stats
14.1.2. Financial Performance & KPIs
14.1.3. Product Portfolio
14.1.4. Business Strategy & Recent
Developments
* Similar details would be provided
for all the players mentioned below
14.2. DreaMed
Diabetes Ltd.
14.3. Beta Bionics,
Inc.
14.4. Bigfoot
Biomedical, Inc.
14.5. Insulet
Corporation
14.6. Medtronic plc
14.7. Admetsys
Corporation
14.8. Diabeloop SA
14.9. TypeZero
Technologies LLC
14.10. Tandem
Diabetes Care, Inc.
14.11. Others
15. Research
Methodology
15.1. External Transportations /
Databases
15.2. Internal Proprietary Database
15.3. Primary Research
15.4. Secondary Research
15.5. Assumptions
15.6. Limitations
15.7. Report FAQs
16. Research Findings & Conclusion
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process